If you have been reading about GHRH analog and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Mental illness is often discussed on social media and several studies have noted a link between it and severe psychiatric disorders. Studies such as one in 1998 led by Robert E. Kraut indicated that Internet can have an impact on a person's daily life and that increased amounts of time online can have a detrimental impact on interpersonal relationships and social interactions, which can in turn lead to increased depression and alienation. Today, social media platforms such as Twitter or Instagram have increased the amount of personal interaction with other users. There is current research that explores the role social media has in assisting people find resources and networks to support one's mental health. The interconnectivity between users through social media has encouraged many to seek help with professionals while also reducing the stigma surrounding mental illnesses. Though these claims are still being researched, there is a notable rise in communication within social media as a whole. The Scottish Health Survey conducted a study monitoring screen time and mental health in individuals. The research concluded that adults ages 16–99 who watch TV more than three hours a day were more likely to have poor mental health. 3 hours or more of television or screen time in children lead to a downward trend in mental health positivity. The study concluded that there is a correlation between screen time and a decline in mental health.
These can then be used to re-cellularise a three-dimensional lung tissue scaffold. A 2010 investigation used the ECM scaffold to produce entire lungs in vitro to be transplanted into living rats. These successfully enabled gas exchange but for short time intervals only. Nevertheless, this was a huge leap towards whole lung regeneration and transplants for humans, which has already taken another step forward with the lung regeneration of a non-human primate. Cystic fibrosis is another disease of the lungs, which is highly fatal and genetically linked to a mutation in the CFTR gene. Through growing patient-specific lung epithelium in vitro, lung tissue expressing the cystic fibrosis phenotype has been achieved. This is so that modelling and drug testing of the disease pathology can be carried out with the hope of regenerative medical applications.
==== Specialized soy sauces and seasonings ==== Since the 2000s, dozens of soy sauces specifically designed for TKG have been marketed by various companies in Japan. These are typically less salty than regular soy sauce and often contain dashi (like kombu or katsuobushi extract) and mirin (sweet rice wine) to complement the egg and rice flavour. Notable examples include:
Sources: en.wikipedia.org
CE capillary is coupled directly to an electrospray ionization source with a sheathless interface system. The electric contact for ESI is realized by using capillary coated with conductive metal. Because no sheath liquid is used, the system has high sensitivity, low flow rates and minimum background. However, these interface designs, all have challenges including low mechanical robustness, poor reproducibility. The latest sheathless interface design features porous ESI emitter through chemical etching. This design effectively provides robust interfacing with mass spectrometry and addresses the reproducibility challenges associated with previous designs. This porous emitter interface has been explored to couple of CITP/CZE (or transient ITP) which greatly improves sample loading capacity of CE and enabled ultrasensitive detection of trace analytes. High reproducibility, robustness and sensitivity were achieved in sheathless transient capillary isatochophoresis (CITP)/capillary zone electrophoresis (CZE) -MS interface, where conductive liquid was used. Conductive liquid contacts with the metal-coated outer surface of the emitter completing the circuit, but at the same time it does not mix with separation liquid and therefore there is no sample dilution.
To increase the level of recycling and meet its targets, Tetra Pak engaged in driving recycling activities such as developing collection schemes, launching new recycling technologies, and raising awareness of recycling and sustainability. Used Tetra Pak packages have been recycled as construction material in design projects, with varying results. By 2017, 25% of Tetra Pak cartons were recycled globally. At that time, the company announced that global recycling rates would no longer be one of its main metrics measured in sustainability reports, abandoning its previous target of increasing recycling rates to 40% by 2020, and instead introduced new metrics to measure against, such as public outreach, access to recycling facilities, and recycling capacity. In 2018, Tetra Pak signed an agreement with the environmental services company Veolia "to recycle all the components of used beverage cartons collected within the EU by 2025." Tetra Pak has also partnered with the Certified Renovated Equipment organization to refurbish old equipment so it can be resold as part of a circular economy initiative. In attempts to innovate and to improve the recyclability rate of their Aseptic cartons, one of the main factors is the replacement of the aluminum layer used, which can constitute up to 5% of the package material. In which, exposure to the metal has been suggested as a risk factor for Alzheimer's Disease. The company is currently testing two alternatives as a replacement for aluminum: (1) a fiber-based barrier layer, and (2) a polymer-based barrier.
AlbuRx, Alburex, Albumeon, Human Albumin Behring, Albuminar 25, human albumin solution (5%, 20% or 25% human albumin solutions) Berinert P, freeze-dried human C1-esterase inhibitor (C1-INH) concentrate Beriplex P/N, freeze-dried human prothrombin complex concentrate Haemocomplettan P, RiaSTAP, freeze-dried human fibrinogen (factor I) concentrate Kybernin P, freeze-dried human antithrombin III concentrate Streptase, freeze-dried streptokinase Wound Healing:
Sources: en.wikipedia.org
Popular party substances have been reported by users to consist of aphrodisiac properties because of their enhancing effects with sexual pleasure. Ecstasy users have reported an increase in sexual desire and sexual pleasure; however, there have been reports of delayed orgasm in both sexes and erectile difficulties in men. Poppers, containing drugs for inhalation, have been linked to increased sexual pleasure. Known adverse effects are headaches, nausea, and temporary erectile difficulties.
=== Bioavailability === In contrast to the intake of CoQ10 as a constituent of food, such as nuts or meat, from which CoQ10 is normally absorbed, there is a concern about CoQ10 bioavailability when it is taken as a dietary supplement. Bioavailability of CoQ10 supplements may be reduced due to the lipophilic nature of its molecule and large molecular weight.
=== Starting material === PMCA was originally based on the normal prion protein (PrPC) from healthy brain tissue, which is expensive. The advent of recombinant proteins have lower the cost somewhat, but the steps required to obtain the pure protein are laborious. In 2011, it was found that simply putting a prion protein transgene into a cell line and then lysing the cell without purification is enough. This is expected to make PMCA much cheaper. The cell line does not need to be of a neuronal origin. PMCA is most easily performed with catalysts which are abundant even in healthy cells: a polyanion (single-stranded RNA or sulfated glycans) and a phospholipid. A cell lysate would provide both of these catalysts and most clumps of PrPSc contain catalyst polyanion molecules anyways. Synthetic versions of these catalysts such as poly(A) RNA and 1-palmitoyl-2-oleoylphosphatidylglycerol (POPG) also work for propagating PrPSc. Additional required materials include buffer salts and detergent.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.